惠柏新材(301555.SZ):擬使用部分募集資金和自有資金向子公司增資以實施募投項目
格隆匯2月28日丨惠柏新材(301555.SZ)公佈,公司於2025年2月27日召開第四屆董事會第七次會議及第四屆監事會第六次會議,審議通過了《關於使用部分募集資金和自有資金向子公司增資以實施募投項目的議案》,同意公司使用部分募集資金和自有資金向全資子公司惠柏新材料科技(珠海)有限公司(簡稱“珠海惠柏”)增資人民幣5,700.00萬元,用於實施珠海惠柏“新建8.2萬噸新型電子專用材料生產項目”,其中:募集資金5,615.00萬元(包括利息收入、理財收益扣減手續費後的淨額等,具體金額以轉出當日募集資金專戶餘額爲準)、不足部分以自有資金補足。本次增資完成後,珠海惠柏的註冊資本將增加至人民幣19,200.00萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.